购物车
全部删除
您的购物车当前为空
CD19 Protein, Human, Recombinant (CHO, hFc) is expressed in CHO Cells. The accession number is P15391.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 μg | ¥ 1,080 | 6-8日内发货 | |
| 10 μg | ¥ 1,725 | 6-8日内发货 | |
| 20 μg | ¥ 2,780 | 5日内发货 | |
| 50 μg | ¥ 4,880 | 5日内发货 | |
| 100 μg | ¥ 7,780 | 5日内发货 | |
| 200 μg | ¥ 12,380 | 5日内发货 | |
| 500 μg | ¥ 21,680 | 5日内发货 |
| 生物活性 | Immobilized Human FMC63 at 2 μg/ml (100 μl/well) can bind Human CD19-Fc. The ED50 of Recombinant Human CD19-Fc is 55.28 ng/ml. Loaded Anti-Human CD19 mAb-Fc on AMC Biosensor, can bind Human CD19-FC with an affinity constant of 2.72 nM as determined in BLI assay. |
| 产品描述 | CD19 Protein, Human, Recombinant (CHO, hFc) is expressed in CHO Cells. The accession number is P15391. |
| 种属 | Human |
| 表达系统 | CHO Cells |
| 标签 | C-Fc |
| 蛋白编号 | P15391 |
| 别名 | CVID3,CD19 molecule,B4 |
| 蛋白构建 | Pro20-Lys291 |
| 蛋白纯度 | > 95% as determined by SDS-PAGE |
| 分子量 | 57.3 kDa (Predicted); 80-95 kDa (Reducing conditions) |
| 内毒素 | < 1.0 EU/μg of the protein as determined by the LAL method. |
| 蛋白性状 | Lyophilized powder |
| 缓冲液 | Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4. |
| 复溶方法 | Reconstitute the lyophilized protein in sterile deionized water. The product concentration should not be less than 100 μg/mL. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| 存储 | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| 研究背景 | CD19 is a single-pass type I membrane protein containing 2 Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. CD19 primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. CD19 Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. |